[IONS] Ionis Pharmaceuticals Thesis 2026: Wainua Tryngolza Launch Drives Independent Commercial Recovery
Key Takeaways
- Ionis Pharmaceuticals Inc. (NASDAQ: IONS) FY2025 revenue ~$590-680M (-15 to -1% YoY) with adj. EPS ~-$2.20 to -$1.65 reflecting selected post-December 2024 ~$30-50M aggregate Tryngolza (olezarsen) FDA approval (selected first-in-class novel familial chylomicronemia syndrome (FCS) treatment) plus selected continued post-2024 ~$200-260M aggregate Spinraza royalty revenue (~30-40% aggregate revenue mix; selected continued Biogen Spinraza partnership) plus selected post-December 2023 ~$50-100M aggregate Wainua (eplontersen) Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis launch + selected continued post-2024 selected various pipeline (selected continued post-2024 selected primary independent commercial transformation toward selected various Ionis-owned pipeline) under continued President + CEO Brett Monia since 2020 (~5-year tenure as Ionis Pharmaceuticals CEO; ex-Ionis Chief Operating Officer + Chief Scientific Officer + ~35-year company career; succeeded post-2020 Stan Crooke retirement who founded Ionis in 1989).
- Wainua + Tryngolza independent commercial launch: post-December 2023 ~$50-100M aggregate Wainua (eplontersen) Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis launch + selected post-December 2024 ~$30-50M aggregate Tryngolza (olezarsen) FDA approval (selected first-in-class novel familial chylomicronemia syndrome (FCS) treatment); selected continued post-2024 selected primary independent commercial transformation toward selected various Ionis-owned pipeline (selected reduce historic dependence on Spinraza Biogen royalty + selected various partner-owned licensing); selected continued post-2024 ~$0.20-0.40 incremental annual EPS contribution.
- Spinraza royalty + selected various pipeline: ~$200-260M aggregate Spinraza royalty revenue FY2025 (~30-40% aggregate revenue mix; selected continued Biogen Spinraza partnership for spinal muscular atrophy SMA pediatric); selected continued post-2024 selected various Ionis-owned pipeline (donidalorsen for hereditary angioedema HAE + selected various olezarsen ApoCIII Other + selected various pelacarsen Lp(a) cardiovascular + selected various RNA-targeted pipeline); selected continued post-2024 ~$0.10-0.20 incremental annual EPS contribution.
- Capital + cash position: selected post-2024 ~$1.6-1.9B aggregate cash + investments balance; selected post-2024 ~$0M aggregate net debt position; selected modest opportunistic buybacks; selected pathway to GAAP profitability inflection FY2026-2028 driven by Wainua + Tryngolza commercialization; investment-grade pathway pre-profitability inflection; FY2026 catalyst: continued Wainua + Tryngolza commercialization + selected potential post-2024 GAAP profitability inflection.
Company Background
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is one of the world's leading RNA-targeted therapeutics + antisense oligonucleotide (ASO) drug development companies with FY2025 revenue ~$590-680M (-15 to -1% YoY) and adj. EPS ~-$2.20 to -$1.65 reflecting selected post-December 2024 ~$30-50M aggregate Tryngolza (olezarsen) FDA approval + selected continued post-2024 ~$200-260M aggregate Spinraza royalty revenue + selected post-December 2023 ~$50-100M aggregate Wainua (eplontersen) Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis launch + selected continued post-2024 selected various pipeline. The company employs ~900+ globally with operations across selected major Carlsbad California + selected various.
Founded 1989 as Isis Pharmaceuticals in Carlsbad California by Stanley Crooke (~36-year heritage; selected pioneer antisense oligonucleotide RNA-targeted drug development); selected post-1991 NASDAQ listing IPO; selected post-2015 Isis Pharmaceuticals → Ionis Pharmaceuticals name change; selected post-2016 Spinraza (nusinersen) FDA approval (selected first ASO drug + selected first SMA treatment) + selected post-2016 Biogen Spinraza partnership commercial launch + selected various royalty revenue stream; selected post-2018 Tegsedi (inotersen) FDA approval; selected post-2020 Brett Monia CEO appointment (selected post-Stan Crooke retirement); selected post-December 2023 Wainua (eplontersen) Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis FDA approval + commercial launch; selected post-December 2024 Tryngolza (olezarsen) FDA approval for familial chylomicronemia syndrome (FCS) (selected first-in-class novel FCS treatment).
Headquartered in Carlsbad California; ~900+ employees globally with ~$590-680M revenue. Three primary product + pipeline segments: Ionis-owned Commercial (~25-30% revenue ~$150-200M — selected post-December 2023 Wainua + selected post-December 2024 Tryngolza + selected various Ionis-owned), Spinraza Royalty + Selected Various Royalties (~35-40% revenue ~$220-300M — selected continued Biogen Spinraza partnership + selected various royalties), R&D Revenue + Pipeline (~30-35% revenue ~$200-250M — selected various pipeline development + selected various). Geographic mix: US 60-65% revenue ($355-440M) + Europe + selected various international 25-30% ($150-200M; selected primary Spinraza ex-US royalties) + selected various 10% ($60-70M).
President + CEO Brett Monia since 2020 (~5-year tenure as Ionis Pharmaceuticals CEO); succeeded Stan Crooke (Founder + CEO 1989-2020 retired who founded Ionis in 1989 + led through 2016 Spinraza FDA approval); Monia ex-Ionis Chief Operating Officer + Chief Scientific Officer + ~35-year company career; selected continued strategic priorities include independent commercial transformation toward selected various Ionis-owned pipeline + selected continued post-December 2023 Wainua + selected post-December 2024 Tryngolza commercialization + selected continued post-2024 selected various RNA-targeted pipeline development + selected continued post-2024 capital deployment. CFO Beth Hougen (since 2018; ex-Ionis VP Finance + ex-various roles + ~25-year company career).
Wainua + Tryngolza Independent Commercial Launch
Ionis Pharmaceuticals Wainua + Tryngolza independent commercial launch:
- Wainua (eplontersen) launch: post-December 2023 ~$50-100M aggregate Wainua Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis launch
- Tryngolza (olezarsen) FDA approval: post-December 2024 ~$30-50M aggregate Tryngolza FDA approval (selected first-in-class novel familial chylomicronemia syndrome FCS treatment)
- Independent commercial transformation: selected continued post-2024 selected primary independent commercial transformation toward selected various Ionis-owned pipeline
- Selected reduce historic dependence on Spinraza Biogen royalty: continued post-2024 selected various
- Selected continued post-2024 ~$0.20-0.40 incremental annual EPS contribution: continued post-2024
FY2026 catalyst: continued Wainua + Tryngolza commercialization + ~$0.20-0.40 incremental annual EPS contribution.
Spinraza Royalty + Selected Various Pipeline
Ionis Pharmaceuticals Spinraza royalty + selected various pipeline:
- Spinraza royalty revenue: ~$200-260M aggregate FY2025 (~30-40% aggregate revenue mix)
- Biogen Spinraza partnership: selected continued Biogen Spinraza partnership for spinal muscular atrophy SMA pediatric
- Donidalorsen (hereditary angioedema HAE): selected various Ionis-owned pipeline
- Olezarsen ApoCIII + selected various: selected continued post-2024 selected various
- Pelacarsen Lp(a) cardiovascular: selected continued post-2024 selected various
- Selected continued post-2024 ~$0.10-0.20 incremental annual EPS contribution: continued post-2024
FY2026 catalyst: continued Spinraza royalty + Ionis-owned pipeline + ~$0.10-0.20 incremental EPS contribution.
Capital + Cash Position
Ionis Pharmaceuticals capital + cash position framework + GAAP profitability inflection:
- Cash + investments balance: ~$1.6-1.9B aggregate FY2025
- Net debt position: ~$0M aggregate FY2025
- Selected modest opportunistic buybacks: continued post-2024 selected various
- Selected pathway to GAAP profitability inflection: FY2026-2028 selected pathway driven by Wainua + Tryngolza commercialization
- Selected pre-profitability inflection: investment-grade pathway pre-profitability inflection
FY2026 catalyst: continued Wainua + Tryngolza commercialization + selected potential post-2024 GAAP profitability inflection.
Risks
- Selected various competitive intensity: Alnylam Pharmaceuticals + selected various RNA-targeted + ASO competitive
- Selected continued post-2024 Spinraza generic erosion: continued post-2024 Spinraza generic erosion + selected various Biogen + selected various Roche Risdiplam SMA competitive
- Selected post-December 2023 Wainua + post-December 2024 Tryngolza commercialization: continued post-2024 commercialization sustainability
- Selected various clinical pipeline: continued post-2024 various clinical pipeline risk
- Selected continued post-2024 GAAP profitability inflection: continued post-2024 selected various GAAP profitability inflection trajectory
Key Core Metrics
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2026 outlook |
|---|---|---|---|---|---|
| Revenue | $590-680M | $688M | $570M | $574M | $700-820M |
| Adj. EBITDA | -$340 to -$280M | -$305M | -$280M | -$215M | -$300 to -$200M |
| Adj. EPS (USD) | -$2.20 to -$1.65 | -$1.85 | -$2.20 | -$1.45 | -$2.00 to -$1.30 |
| Adj. EBITDA margin | n/m (loss) | n/m | n/m | n/m | n/m |
| Cash + investments | $1.6-1.9B | $2.0B | $1.7B | $1.7B | $1.4-1.7B |
| Capital + cash | FY2025 | FY2024 | FY2026 outlook |
|---|---|---|---|
| Cash + investments | $1.6-1.9B | $2.0B | $1.4-1.7B |
| Net debt | $0M | $0M | $0M |
| Buybacks | modest | modest | modest |
| Total return | n/a | n/a | n/a |
Market Evaluation
Ionis Pharmaceuticals trades at selected ~negative-25x FY2026 P/E premium vs Alnylam Pharmaceuticals (~30-40x) + Vertex Pharmaceuticals (~22-25x) + selected various biotechnology peers reflecting selected post-December 2024 ~$30-50M aggregate Tryngolza FDA approval + selected continued post-2024 ~$200-260M aggregate Spinraza royalty + selected post-December 2023 ~$50-100M aggregate Wainua launch + selected continued post-2024 ~$1.6-1.9B aggregate cash + investments balance + selected pathway to GAAP profitability inflection FY2026-2028. Selected re-rating catalysts include: (1) continued Wainua + Tryngolza independent commercial launch + selected continued post-2024 ~$0.20-0.40 incremental annual EPS contribution; (2) selected continued Spinraza royalty + selected various Ionis-owned pipeline; (3) selected continued post-2024 selected various RNA-targeted pipeline development; (4) selected pathway to GAAP profitability inflection FY2026-2028; (5) selected continued post-2024 ~$1.4-1.9B aggregate cash + investments balance.
Wainua + Tryngolza + RNA-Targeted Strategic Differentiation Deep Dive
Ionis Pharmaceuticals RNA-targeted therapeutics + antisense oligonucleotide (ASO) franchise + selected post-December 2024 Tryngolza FDA approval + selected post-December 2023 Wainua Ionis-AstraZeneca commercial launch represent selected primary strategic differentiation thesis vs traditional RNA-targeted + ASO biotechnology peers (Alnylam Pharmaceuticals + selected various). Selected post-December 2023 ~$50-100M aggregate Wainua (eplontersen) Ionis-AstraZeneca hereditary transthyretin (hATTR) amyloidosis launch + selected post-December 2024 ~$30-50M aggregate Tryngolza (olezarsen) FDA approval (selected first-in-class novel familial chylomicronemia syndrome (FCS) treatment) + selected continued post-2024 selected primary independent commercial transformation toward selected various Ionis-owned pipeline (selected reduce historic dependence on Spinraza Biogen royalty + selected various partner-owned licensing) + selected continued post-2024 ~$0.20-0.40 incremental annual EPS contribution supports selected primary Wainua + Tryngolza independent commercial launch thesis. Selected continued post-2024 ~$200-260M aggregate Spinraza royalty revenue (~30-40% aggregate revenue mix; selected continued Biogen Spinraza partnership for spinal muscular atrophy SMA pediatric) + selected continued post-2024 selected various Ionis-owned pipeline (donidalorsen for hereditary angioedema HAE + selected various olezarsen ApoCIII Other + selected various pelacarsen Lp(a) cardiovascular + selected various RNA-targeted pipeline) supports selected continued post-2024 Spinraza royalty + selected various pipeline thesis. Selected post-2024 ~$1.6-1.9B aggregate cash + investments balance + selected ~$0M aggregate net debt position + selected modest opportunistic buybacks + selected pathway to GAAP profitability inflection FY2026-2028 driven by Wainua + Tryngolza commercialization supports selected continued post-2024 capital flexibility. Selected post-2020 Brett Monia CEO appointment (selected ex-Ionis COO + Chief Scientific Officer + ~35-year company career) supports selected continued post-2020 strategic priorities. FY2026 catalyst: continued Wainua + Tryngolza + Spinraza royalty + ~$0.20-0.40 incremental annual EPS contribution.
FY2026 thesis: Wainua + Tryngolza independent commercial launch + Spinraza royalty + selected various Ionis-owned pipeline + ~$1.6-1.9B aggregate cash + investments balance + ~$0M aggregate net debt + selected pathway to GAAP profitability inflection FY2026-2028 + selected potential post-2024 capital return optionality.